Trial Profile
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Sponsors AnGes MG
- 25 Sep 2014 New trial record